Review anchor
Vascular endothelial growth factor A, long form
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Vascular endothelial growth factor A, long form
CHEMBL1783
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Vascular endothelial growth factor A, long form as ChEMBL target CHEMBL1783, mapped to UniProt P15692. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1783
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P15692
Vascular endothelial growth factor A, long form
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Vascular endothelial growth factor A, long form matters
Vascular endothelial growth factor A, long form is reviewed as Vascular endothelial growth factor A, long form (UniProt P15692); Vascular endothelial growth factor A, long form shows approved-linked disease relevance led by wet macular degeneration. 5 more disease programs remain visible in the same review block.; 9 linked drugs keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 330 compounds, and 58 assays, with lead potency reaching pChEMBL 10.6.
Protein context
Vascular endothelial growth factor A, long form
Vascular endothelial growth factor A, long form Sequence length is 395 aa.
Review this target as Vascular endothelial growth factor A, long form, mapped to UniProt P15692. Sequence length is 395 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P15692
Protein
Disease context
wet macular degeneration
Vascular endothelial growth factor A, long form shows approved-linked disease relevance led by wet macular degeneration. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABICIPAR PEGOL, AFLIBERCEPT, BEVACIZUMAB.
Start review with wet macular degeneration because it currently carries approved-linked support. Linked drugs include ABICIPAR PEGOL, AFLIBERCEPT, BEVACIZUMAB, BEVACIZUMAB GAMMA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
9 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 330 compounds, and 58 assays for this target. The dominant activity type is EC50. CHEMBL3219623 is the current potency anchor at pChEMBL 10.6.
Use CHEMBL3219623 as the tractability anchor when discussing potency (pChEMBL 10.6).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 10.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Vascular endothelial growth factor A, long form matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P15692, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why wet macular degeneration is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
330
Total Compounds
58
Total Assays
2
Approved Drugs
IC50: 190.0, EC50: 264.0, KD: 96.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3219623
|
10.6 | Kd | — |
|
|
No preferred name
CHEMBL3219622
|
10.6 | Kd | — |
|
|
No preferred name
CHEMBL3234202
|
9.9 | IC50 | — |
|
|
No preferred name
CHEMBL3234200
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL2022564
|
9.5 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
BELZUTIFAN
CHEMBL4585668
|
2021 |
Source Header